Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Tirzepatide [2023788-19-2]

Research Use Only
AG-CP3-0043
AdipoGen Life Sciences
CAS Number2023788-19-2
Product group Chemicals
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Tirzepatide
  • Delivery Days Customer
    10
  • CAS Number
    2023788-19-2
  • Certification
    Research Use Only
  • Scientific Description
    Chemical. CAS: 2023788-19-2. Formula: C225H348N48O68. MW: 4813.5. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13). - Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13).
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200